Facebook
Twitter
LinkedIn
ForwardMiami Cancer Institute Multispecialty Grand Rounds: From Empiric Data-Driven Radiation Oncology – Integrating Genomics into RT Prescription
The current radiation therapy prescription paradigm is based on an empiric one-size fits all where all patients are treated to the same uniform dose of radiation therapy (RT). This practice is in direct conflict with the realization that cancer is the most heterogeneous disease that afflicts humans. Our hypothesis is that this empiric approach while safe and effective does not optimize the tumor dose for each individual patient. We have developed radiosensitivity index (RSI) a gene expression signature of tumor radiosensitivity and genome-based model for adjusting radiotherapy dose (GARD) an estimate of the clinical effect of a given dose of RT. RSI/GARD provide the first approach to optimize the tumor dose for each individual patient based on genomic features of the tumor. We believe that this approach provides the first data-driven system for optimization of RT tumor dose in radiation oncology.
In this lecture Dr. Torres-Roca will discuss the clinical evidence supporting the RSI/GARD prescription system and will propose a way forward to utilize biological data to optimize RT tumor dose.
Target Audience
Oncologists, Radiation Oncologists, Hematology Oncologists, Radiation Therapists, General Surgeons, General Practitioners, Obstetricians and Gynecologists, Nurses, Pharmacists, Respiratory Therapists, Patient Navigators and all other interested healthcare professionals.
Learning Objectives
- Implement radiogenomics to predict normal tissue sensitivity.
- Discuss various frameworks for modeling radiosensitivity and how radiogenomics can augment these models.
Javier F. Torres-Roca, M.D.
Senior Member
Department of Radiation Oncology
Moffitt Cancer Center
Tampa, Florida
Javier F. Torres-Roca, M.D., faculty of this educational activity, has received royalties/patent beneficiary from CvergenX, Inc. He is also the owner and has individual stocks/stock options with CvengenX, inc. Dr. Torres-Roca has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Guilherme Rabinowits, M.D., conference series director, has indicated that he is an advisor with Sanofi-Genzyme, Regeneron, Castle and Boston Gene. All of the relevant financial relationships listed for this individual have been mitigated.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationship(s) to disclose with ineligible companies*
*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-680158, by the Florida Boards of Medicine, Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nurse Practitioners, Nurses, Pharmacists and Techs and Respiratory Therapists. Baptist Health South Florida CE Broker Provider #50-182.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
- 1.00 Florida Board of Pharmacy
- 1.00 Florida Board of Respiratory Therapy
Required Hardware/Software
 | PC/Mac UsersThis site is supported on the most recent stable releases of the following browsers:
| ||||||
 | Mobile UsersThis site is supported on the following mobile devices:
| ||||||
 | Technical SupportIf you are experiencing technical difficulties or have received an error message, please send an email to [email protected] and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours. |
